TABLE 1.

Patient Characteristics at time of study inclusion

Patient	Age	Diagnosis	Conditioning regimen	GvHD prophylaxis	Preceeding aGvHD	CMV infection	Months from HSCT to cGvHD diagnosis	Months from cGvHD to inclusion	Previous lines of cGvHD therapy	Prednisone dose at inclusion (mg/day)
1	59	AML	Flu+Bu	CyA+Mtx	No	No	25	14	CyA+prednisone, MMF, ECP, Mtx	10
2	61	Myelo‐fibrosis	Flu+Bu	CyA+Mtx+ATG	Yes	No	5	11	CyA+ prednisone, tacrolimus+sirolimus, imatinib, ECP	50
3	56	CLL	Flu+Cy+TBI	Tacrolimus+sirolimus	—	—	9	18	Tacrolimus+ prednisone, Rituximab	7.5
4	50	AML	Bu+Cy	CyA+Mtx	—	—	7	6	CyA+ prednisone	50
5	38	AML	Bu+Cy	CyA+Mtx	Yes	Yes	11	37	CyA+ prednisone, Mtx	15
6	30	HL	Flu+Cy+TBI	CyA+Mtx	Yes	No	8	34	CyA+ prednisone, Mtx, rituximab, ECP, MMF	3.75
7	41	MM	Flu+TBI	CyA+Mtx	No	No	3	9	CyA+prednisone, infliximab	30
8	20	AML	Bu+Cy	CyA+Mtx	Yes	Yes	7	57	CyA+ prednisone, sirolimus, MMF, infliximab, rituximab, tacrolimus, ECP, imatinib, chloroquin, DSC	15
9	53	AML	Bu+Cy	CyA+MMF	Yes	No	18	42	Tacrolimus+ prednisone, thalidomide, imatinib, ECP	0
10	60	AML	Flu+Bu	CyA+Mtx	Yes	No	7	70	CyA+MMF, prednisone, rituximab, Mtx	0
11	29	ALL	Cy+TBI	Tacrolimus+sirolimus	No	No	15	6	Tacrolimus+ prednisone, imatinib	12.5

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; cGvHD, chronic graft‐vs‐host disease; CLL, chronic lymphocytic leukemia; CyA, cyclosporin A; DSC, decidual stromal cells; ECP, extracorporeal photopheresis; HL, Hodgkins lymphoma; HSCT, hematopoietic stem cell transplantation; MM, multiple myeloma; MMF, mycophenolate mofetil; Mtx, methotrexate.